Moleculin(MBRX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update HOUSTON, May 13, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the quarter ended March 31, 2024. As previously announced, the Company will host a conference call and live audio webcast to discuss the ...